Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia
Part of paid clinical trials in Dallas, Texas.
- Sponsor
- Methodist Health System
- Study ID
- NCT06223607
- Status
- Recruiting
Conditions
- Baseline Thrombocytopenia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).
Key Dates
- Start date
- Aug 22, 2022
- Status verified
- Jan 2026
- Primary completion
- Dec 28, 2026
- Completion
- Dec 22, 2027
Study Design
- Enrollment
- 300 participants (estimated)
Primary Outcome Measure
Incidence of bleeding [ Time Frame: 1 year ]
Central Contacts
- Bethany Brauer214-947-4681
- Colette Ngo Ndjom214-947-1289
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Methodist Dallas Medical Center | Dallas | Texas | 75203 | Jessica Rago Crotty, Pharm D (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Dallas, TX
By research site